Workflow
GREEN FRESH BIO(01084)
icon
Search documents
绿新生物科技(01084) - 董事会会议通告
2025-08-15 12:09
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責,對其準確性或完 整性亦不發表任何聲明,並明確表示,概不就因本公告全部或任何部分內容而產生或因倚賴該等內 容而引致之任何損失承擔任何責任。 綠新生物科技有限公司 (於開曼群島註冊成立的有限公司) (股份代號:1084) 董事會會議通告 GREEN FRESH BIOTECHNOLOGY COMPANY LIMITED 綠新生物科技有限公司(「本公司」)董事(「董事」)會(「董事會」)謹此宣佈,本公司將 於二零二五年八月二十八日(星期四)舉行董事會會議,藉以(其中包括)批准刊發本 公司及其附屬公司截至二零二五年六月三十日止六個月的中期業績,並考慮派發中 期股息(如有)的推薦建議。 承董事會命 綠新生物科技有限公司 主席兼行政總裁 陳金淙 香港,二零二五年八月十五日 截至本公告日期,執行董事為陳金淙先生(主席兼行政總裁)、郭東旭先生、陳垂燁先生、佘小迎先 生及陳熠女士;以及獨立非執行董事為何貴清先生、吳文拱先生及胡國華先生。 ...
绿新生物科技发盈警 预期上半年公司拥有人应占亏损净额约1100万-1350万元 同比盈转亏
Zhi Tong Cai Jing· 2025-08-08 10:19
Core Viewpoint - The company expects to report a net loss attributable to shareholders of approximately RMB 11 million to 13.5 million in the first half of 2025, compared to a net profit of RMB 23.08 million in the same period of 2024 [1] Group 1: Financial Performance - The anticipated decline in performance is primarily due to a decrease in both the selling price and sales volume of the company's main hydrophilic colloid products, leading to reduced revenue and gross profit during the reporting period [1] - The company has increased its research and development expenditures related to the technology and knowledge for current mainstream products and new products during the reporting period [1]
绿新生物科技(01084)发盈警 预期上半年公司拥有人应占亏损净额约1100万-1350万元 同比盈转亏
Zhi Tong Cai Jing· 2025-08-08 10:16
Core Viewpoint - Green New Bio-Tech (01084) expects to report a net loss attributable to shareholders of approximately RMB 11 million to 13.5 million for the first half of 2025, a significant decline from a net profit of RMB 23.08 million in the same period of 2024 [1] Summary by Relevant Categories Financial Performance - The company anticipates a net loss of approximately RMB 11 million to 13.5 million for the first half of 2025, compared to a net profit of RMB 23.08 million in the first half of 2024 [1] Factors Affecting Performance - The decline in performance is primarily attributed to a decrease in both the selling price and sales volume of the company's main hydrophilic colloid products, leading to reduced revenue and gross profit during the reporting period [1] - There has been an increase in research and development expenses related to the technology and knowledge for producing current mainstream products and new products during the reporting period [1]
绿新生物科技(01084) - 截至二零二五年六月三十日止六个月之盈利警告
2025-08-08 10:06
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責,對其準確性或完 整性亦不發表任何聲明,並明確表示,概不就因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致之任何損失承擔任何責任。 GREEN FRESH BIOTECHNOLOGY COMPANY LIMITED 綠新生物科技有限公司 (於開曼群島註冊成立的有限公司) (股份代號:1084) 截至二零二五年六月三十日止六個月之盈利警告 本公告乃綠新生物科技有限公司(「本公司」,連同其附屬公司,統稱「本集團」)董事 (「董事」)會(「董事會」)根據香港聯合交易所有限公司證券上市規則(「上市規則」)第 13.09(2)條以及香港法例第571章證券及期貨條例第XIVA部內幕消息條文作出。 經初步審閱現有可得資料(包括但不限於本集團截至二零二五年六月三十日止六個 月(「報告期間」)的未經審核綜合管理賬目)後,董事會謹此通知本公司股東(「股 東」)及有意投資者,於報告期間,本公司預期錄得本公司擁有人應佔虧損淨額介乎 約人民幣11.0百萬元至人民幣13.5百萬元,而截至二零二四年六月三十日止六個月 的本公司擁有人應佔純利為人民幣23.08百萬 ...
绿新生物科技(01084) - 股份发行人的证券变动月报表
2025-08-01 02:54
股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致:香港交易及結算所有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01084 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 50,000,000,000 | HKD | | 0.01 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 50,000,000,000 | HKD | | 0.01 | HKD | | 500,000,000 | 本月底法定/註冊股本總額: HKD 500,000,000 FF301 第 1 ...
2025年中国琼脂行产业链图谱、市场供需现状、进出口贸易、竞争格局及发展趋势:绿新亲水胶体龙头优势明显[图]
Chan Ye Xin Xi Wang· 2025-07-22 01:34
内容概要:随着国民健康意识的不断提升,对天然、绿色食品的需求日益增加,琼脂作为天然植物胶, 符合这一消费趋势,在食品领域的应用更加广泛,不仅在果冻、布丁等传统食品中占据重要地位,还在 更多新型健康食品中得到应用,如一些低糖、低脂的乳制品和肉制品等,同时,医药行业中,生物制药 技术不断发展,琼脂作为培养基成分,需求量也不断上升,此外,琼脂因其具有良好的保湿性和稳定 性,面膜、爽肤水等化妆品市场应用也日益广泛,据统计,2024年我国琼脂销量达销量1.46万吨,但受 产品价格下滑影响,2024年我国琼脂市场规模有所下滑,降至12.66亿元。 上市企业:绿新亲水胶体(01084.HK)、环海生物(838114.NQ) 相关企业:广东海珍海藻生物科技有限公司、上海北连生物科技有限公司、普宁市惠翔海藻工业有限公 司、成都协力魔芋科学种植加工园有限公司、青岛聚大洋藻业集团有限公司、武汉泰科生物技术有限公 司 关键词:琼脂产业链、琼脂供需现状、琼脂市场规模、琼脂竞争格局、琼脂发展趋势 一、概述 琼脂,又称琼胶、洋菜、洋粉、冻粉等,是以海生植物红藻类中的江蓠菜,龙须菜等为原料,采用科学 方法加工提炼而成的天然高分子多糖物质。具 ...
2025年中国亲水胶体行发展历程、产业链图谱、市场规模、竞争格局及发展趋势:行业集中度处于中等水平,细分赛道龙头优势明显[图]
Chan Ye Xin Xi Wang· 2025-07-21 01:34
Overview - Hydrophilic colloids are natural food additives that align with the increasing consumer demand for green, eco-friendly, and healthy products, leading to a growing acceptance and recognition among consumers [1][8] - The market for hydrophilic colloids is expanding, with projected sales in China reaching 175,800 tons by 2024, accounting for 36.72% of the global market [1][8] Development History - Since the 1990s, domestic companies have recognized the importance of independent research and development, leading to increased investment and a shift from imitation to innovation in the hydrophilic colloid industry [4] - The industry has entered a rapid development phase, supported by government initiatives and expanding market demand, resulting in a more complete industrial chain [4] Industry Chain - The upstream raw materials for natural hydrophilic colloids primarily come from agriculture and forestry, while synthetic colloids are produced through chemical synthesis [6] - The downstream applications span various sectors, including food and beverage, pharmaceuticals, daily chemicals, and textiles, enhancing product quality and stability [6] Current Market Situation - The demand for hydrophilic colloids is driven by the growing health consciousness among consumers, leading to broader applications in food, pharmaceuticals, and cosmetics [1][8] - The market is characterized by a diverse range of products, with significant growth in high-value applications [1][8] Competitive Landscape - The hydrophilic colloid industry in China features numerous participants, with varying focuses on different segments, such as gelatin, carrageenan, and konjac gum [10] - Major listed companies include Green New Hydrophilic Colloid, Dongbao Biological, and Yizhi Konjac, with Green New Hydrophilic Colloid leading in revenue at 989 million yuan for 2024 [10][13][15] Future Trends - Companies are expected to increase R&D investments to develop hydrophilic colloids with enhanced properties, including higher stability and additional functionalities [17] - The industry will face stricter environmental standards, prompting a focus on sustainable materials and green production processes to meet market demands for eco-friendly products [17]
研判2025!中国卡拉胶行业PEST分析、产业链图谱、供需现状、进出口贸易、竞争格局及发展趋势分析:食品工业为最大消费市场,占比超70%[图]
Chan Ye Xin Xi Wang· 2025-07-17 01:58
Overview - The demand for carrageenan is increasing in the food industry due to rising health consciousness and the preference for natural additives among consumers [1][10] - In the pharmaceutical sector, carrageenan is recognized for its biocompatibility and biodegradability, making it suitable for drug delivery systems and wound dressings [1][10] - China has become a major producer and consumer of carrageenan, with projected sales reaching 67,300 tons in 2024, although market size is expected to decline to 2.872 billion yuan due to falling product prices [1][10] Industry Background - Economic development and rising income levels in China are driving demand for carrageenan across various sectors, particularly food, cosmetics, and pharmaceuticals [4] - The food industry is the primary application area for carrageenan, accounting for over 70% of consumption, with a growing need for high-quality products [8] Industry Chain - The upstream of the carrageenan industry includes the cultivation and harvesting of red algae, while the downstream encompasses applications in food, medical, cosmetic, and agricultural sectors [6] - Carrageenan is widely used in beverages, candies, and meat processing for thickening and stabilizing, and in cosmetics for its moisturizing properties [6] Market Dynamics - In 2024, China's carrageenan export volume is expected to reach 25,200 tons, with an export value of approximately 20.84 million USD [12] - Major export destinations include Spain, Russia, and the Philippines, with significant revenue contributions from these markets [12] Competitive Landscape - The carrageenan market in China is becoming increasingly competitive, with key players including Green New Hydrophilic Gels, Zhejiang Shangfang Biotechnology, and Fujian Green Power Biotechnology [14][19] - Green New Hydrophilic Gels reported a revenue of 989 million yuan in 2024, with a gross profit margin of 22.49% [17] Future Trends - The application of carrageenan is expected to expand in biotechnology, particularly in tissue engineering and regenerative medicine [21] - There is a growing emphasis on sustainable production practices, with companies likely to adopt green technologies and biodegradable products to meet market demands for environmentally friendly options [21]
绿新生物科技(01084) - 2024 - 年度财报
2025-04-29 13:10
Market Position and Production Capacity - The company maintains its market leadership, being recognized as the largest global producer of agar and refined and semi-refined carrageenan products for 2023 and 2024, according to a report by Frost & Sullivan[5][18]. - As of December 31, 2024, the total designed production capacity is 27,390 tons, including 7,265 tons of agar, 10,355 tons of carrageenan, 1,500 tons of konjac composite products, and 3,300 tons of blended products[6]. - The company completed the acquisition of 82% of Hong Tai Shun International Trading Co., which holds 99.83% of PT Hongxin Algae International, enhancing its production capacity for semi-refined carrageenan by 4,300 tons annually[10]. - The designed production capacity for konjac gum products at the Shiyan Haiyi production base is 660 tons annually, maintaining the same capacity as in 2023[6]. - The company has been recognized as the leading producer of carrageenan and agar in China for 2020 and 2021, and continues to hold this position for 2023 and 2024[17][18]. Financial Performance - For the fiscal year 2024, the company's revenue was RMB 989.3 million, a decrease of RMB 184.7 million or 15.7% compared to RMB 1,174.0 million in 2023[36]. - The gross profit for fiscal year 2024 increased by RMB 184.8 million or 491.0%, resulting in a gross margin of 22.5%, up 19.3 percentage points from the previous year[37]. - The net profit for fiscal year 2024 was RMB 60.9 million, a turnaround from a net loss of RMB 85.4 million in 2023, representing an increase of RMB 146.3 million[37]. - Sales revenue from carrageenan products decreased by RMB 220.9 million or 31.2% compared to the previous year, primarily due to a decline in seaweed material prices[36]. - The sales revenue from compound products increased by RMB 29.1 million or 17.4% in fiscal year 2024[36]. - The total asset value for fiscal year 2024 was RMB 1,572.3 million, an increase from RMB 1,205.3 million in 2023[26]. - The net debt to total asset ratio for fiscal year 2024 was 26.9%, compared to 24.3% in 2023[29]. - The group's revenue for fiscal year 2024 was RMB 989.3 million, a decrease of RMB 184.7 million or 15.7% compared to RMB 1,174 million in fiscal year 2023[54]. - The group's gross profit for fiscal year 2024 was RMB 222.5 million, an increase of RMB 184.9 million or 491.8% compared to fiscal year 2023[58]. - The overall gross profit margin for fiscal year 2024 was 22.5%, an increase of 19.3 percentage points from fiscal year 2023[58]. Research and Development - The number of R&D personnel increased to 106 in 2024, up from 80 in 2023, indicating a focus on innovation and product development[7]. - The company launched the production of agarose microspheres in 2022, aimed at the biopharmaceutical sector, indicating a diversification of its product offerings[10]. - The company established "Xiamen Blue Seaweed Film Biotechnology Co., Ltd." in July 2023 to develop 100% biodegradable seaweed films for beauty masks and plastic alternatives, reflecting its commitment to sustainability[10]. Corporate Governance and Management - The board of directors includes independent non-executive directors who have confirmed their independence as per the listing rules[100]. - The company emphasizes high standards of corporate governance, which are crucial for balancing the interests of shareholders, customers, and employees[168]. - The board has appointed Mr. Chen Jincong as both Chairman and CEO, emphasizing the importance of his leadership in the group's strategic planning and business development[176]. - The company has established appropriate insurance arrangements for directors and senior officers facing legal claims[186]. - The board confirmed that there are no significant uncertainties regarding the company's ability to continue as a going concern[196]. Employee Relations and Compensation - The group has 1,148 full-time employees as of December 31, 2024, with 961 located in mainland China and 187 in Hong Kong and other regions[73]. - Competitive compensation packages are offered to employees, with regular reviews based on group performance and individual contributions[73]. - The company has maintained competitive compensation to attract and motivate employees, with no major disputes with customers or suppliers during the year[97]. Environmental and Regulatory Compliance - The company has not recorded any environmental violations or exceeded environmental standards during the reporting period[98]. - The company has complied with all relevant laws and regulations without any significant violations during the review period[99]. Shareholder Information and Dividends - The company proposed a final cash dividend of HKD 0.012 per share for the fiscal year 2024, totaling HKD 10.5 million[40]. - As of December 31, 2024, the company's distributable reserves were approximately RMB 867 million[93]. - The company proposed a final dividend of HKD 0.012 per share, totaling HKD 10.5 million, compared to HKD 0 in the previous year[90]. Future Outlook - The company expects a rebound in global demand for hydrophilic colloid products in the foreseeable future, driven by a decline in seaweed prices and an anticipated increase in customer demand[38]. - The group anticipates a rebound in global demand for hydrophilic colloid products in the foreseeable future, supported by a decrease in seaweed sales prices[49]. Audit and Risk Management - The audit committee consists of three independent non-executive directors, with Mr. He Guicheng serving as the chairman, responsible for reviewing financial statements and overseeing risk management policies[164]. - The internal audit department is responsible for reviewing operational, financial, and compliance controls to ensure adherence to the group's risk management and internal control policies[200]. - Audit results and control deficiencies are reported to management responsible for ensuring timely remediation[200].
绿新生物科技(01084) - 2024 - 年度业绩
2025-03-31 13:49
Financial Performance - Revenue for the fiscal year 2024 was RMB 989.3 million, a decrease of 15.7% compared to RMB 1,174.0 million in fiscal year 2023[3] - Gross profit was RMB 222.5 million with a gross margin of 22.5%, an increase of RMB 184.9 million and 19.3 percentage points from RMB 37.6 million and 3.2% in fiscal year 2023[3] - The profit for the fiscal year 2024 was RMB 60.9 million, with a net profit margin of 6.1%, an increase of RMB 146.3 million and 13.4 percentage points from a net loss of RMB 85.4 million and a net loss margin of 7.3% in fiscal year 2023[3] - Basic and diluted earnings per share for the fiscal year 2024 were RMB 0.074, compared to a loss of RMB 0.103 in fiscal year 2023[4] - The group’s net profit for the fiscal year 2024 was RMB 609 million, a significant increase of RMB 1.463 billion compared to a net loss of RMB 854 million in fiscal year 2023[55] Assets and Liabilities - Total assets as of December 31, 2024, were RMB 1,572.3 million, an increase from RMB 1,543.6 million as of December 31, 2023[6] - Total equity increased to RMB 850.1 million from RMB 754.1 million year-over-year[7] - Non-current liabilities rose to RMB 126.4 million from RMB 92.4 million in the previous year[7] - Cash and bank balances increased to RMB 120.7 million from RMB 72.6 million year-over-year[6] - The total amount of trade and other receivables reached RMB 149,536,000 in 2024, up from RMB 127,337,000 in 2023[39] Revenue Breakdown - Revenue from the Chinese market was RMB 475,237,000 in 2024, down from RMB 595,174,000 in 2023, reflecting a decrease of about 20.2%[22] - Sales revenue from carrageenan products decreased by RMB 220.9 million or 31.2% due to a decline in seaweed material prices[56] - The sales value in the Chinese market for fiscal year 2024 was RMB 475.2 million, a decrease of RMB 119.9 million or 20.1% compared to fiscal year 2023[57] Expenses - The cost of raw materials and consumables used in 2024 was RMB 598,374,000, down from RMB 884,780,000 in 2023, representing a reduction of 32.4%[25] - Research and development expenses for 2024 amounted to RMB 22,808,000, an increase of 46.1% from RMB 15,589,000 in 2023[26] - The total employee benefits expense for 2024 was RMB 117,576,000, slightly down from RMB 117,866,000 in 2023[25] - The group's sales and distribution expenses rose to RMB 20.6 million, an increase of RMB 2.8 million or 15.7% due to more overseas sales representatives[61] - Administrative expenses increased by RMB 7.3 million or 7.5% to RMB 104.6 million, primarily due to increased material costs in R&D functions[62] Dividends and Shareholder Returns - The company proposed a final cash dividend of HKD 0.012 per share, subject to shareholder approval[2] - The proposed final dividend for 2024 is HKD 0.012 per share, totaling approximately RMB 9,713,000, compared to zero in 2023[38] - The company plans to pay a final cash dividend of HKD 0.012 per share, totaling HKD 10.5 million, to share its operational results with shareholders[54] Corporate Governance - The company confirmed adherence to the corporate governance code, with the exception of the separation of the roles of chairman and CEO as per code provision C.2.1[90] - The company has adopted the principles and provisions of the corporate governance code as its governance framework since its listing[89] - The audit committee, consisting of three independent non-executive directors, reviewed the company's annual performance and financial statements for the fiscal year 2024[93] Future Outlook and Investments - The company is currently evaluating the comprehensive impact of new accounting standards and interpretations on its operations[17] - The company expects that newly issued accounting standards will not have a significant impact on its financial reporting in the foreseeable future[16] - The group plans to invest further in expanding the production capacity of Hongxin using internal resources in the foreseeable future[77] - The group has entered into an investment agreement to inject up to RMB 63.85 million into Xiamen Blue Sea Algae Film Biotechnology Co., Ltd.[73] Market Position and Strategy - The group maintained its market leadership in agar products and refined carrageenan products in China, being recognized as the largest global producer of these products by 2025[48] - The company has launched a 100% biodegradable seaweed film as a plastic alternative, aiming to capitalize on global decarbonization opportunities[51] - The group aims to diversify the geographical location of its production facilities to reduce costs and improve product quality and competitiveness[52] Taxation - The income tax expense for 2024 was RMB 19,996,000, compared to a tax benefit of RMB 27,447,000 in 2023[28] - The effective tax rate for 2024 was 25%, up from 24% in 2023[32] - The group’s subsidiaries in Indonesia and Hong Kong are subject to a corporate tax rate of 22% and 16.5%, respectively[29] Compliance and Reporting - The company will publish its annual report for the fiscal year 2024 on its website and the stock exchange website, in compliance with applicable laws and regulations[97] - The company will suspend share transfer registration from June 3, 2025, to June 6, 2025, to determine eligibility for attending the annual general meeting and voting rights[94] - The company confirmed that there were no significant events affecting the group from December 31, 2024, to the date of the announcement[88]